This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
Some drugs used for the treatment of myeloma can increase the risk of venous thromboembolic events. This NICE guidelines outlines how healthcare professionals can manage patients who may be at higher risk of developing VTE in hospital.
This interactive flowchart developed by NICE gives an overview of blood and bone cancer diagnosis, management and treatment as well as NHS service organisation recommendations.
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
In this guidance NICE outlines recommendations for the use of erythropoiesis-stimulating agents for the treatment of anaemia in cancer patients undergoing chemotherapy.
This NICE guidance outlines recommendations for the prevention, identification and management of neutropenic sepsis in people with cancer.
Following consultation on the scope of the guideline we have decided to retain Improving supportive and palliative care for adults with cancer. The title of the new guideline will be changed to End of life care for adults in the last year of life: service delivery. Where there is overlap between the two guidelines we…